Omeros, which develops drugs for the treatment of surgery-related inflammation and pain, will see its quiet period end next Monday, Nov. 16. On October 7, 2009, the company raised $68.2 million by offering 6.8 million shares at $10.00, at the low end of the range of $10.00 to $12.00. Deutsche Bank acted as the lead manager on the deal.
